{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+sequence+2&page=2",
    "query": {
      "intervention": "Vaccine sequence 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+sequence+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T02:52:32.992Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05470400",
      "title": "A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "FP conjugate vaccine (25 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FP conjugate vaccine (200 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 6931 (100 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 6931 (200 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 4571 (200 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 4571 (100 mcg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 44,
      "start_date": "2022-08-15",
      "completion_date": "2024-01-24",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05470400"
    },
    {
      "nct_id": "NCT05913973",
      "title": "Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Pvs230D1-EPA/Matrix-M",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 105,
      "start_date": "2023-08-04",
      "completion_date": "2025-11-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05913973"
    },
    {
      "nct_id": "NCT01487863",
      "title": "Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Metastatic",
        "Hormone Refractory Prostate Cancer",
        "Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "sipuleucel-T",
          "type": "BIOLOGICAL"
        },
        {
          "name": "abiraterone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dendreon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 69,
      "start_date": "2011-12",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 21,
      "location_summary": "La Jolla, California • La Mesa, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01487863"
    },
    {
      "nct_id": "NCT06634797",
      "title": "A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "mRNA-1273.712",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Years to 30 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2024-10-08",
      "completion_date": "2025-01-20",
      "has_results": true,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Huntington Park, California • La Mesa, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06634797"
    },
    {
      "nct_id": "NCT03794128",
      "title": "A Study of Personalized Neoantigen Cancer Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Gastroesophageal Adenocarcinoma",
        "Urothelial Carcinoma",
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Blood collection for research (next-generation sequencing [NGS])",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood collection for research (HLA typing)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Gritstone bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2018-07-25",
      "completion_date": "2020-05-26",
      "has_results": false,
      "last_update_posted_date": "2020-09-11",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • New York, New York • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03794128"
    },
    {
      "nct_id": "NCT05422781",
      "title": "Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ITI-3000",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunomic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-06-13",
      "completion_date": "2023-06-27",
      "has_results": false,
      "last_update_posted_date": "2023-11-22",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05422781"
    },
    {
      "nct_id": "NCT00300950",
      "title": "Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "GI-4000",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlobeImmune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2006-01",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-04-06",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00300950"
    },
    {
      "nct_id": "NCT04019444",
      "title": "Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rabies",
        "Rabies Immunisation"
      ],
      "interventions": [
        {
          "name": "ChAd155-RG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Rabies Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2019-09-19",
      "completion_date": "2023-03-24",
      "has_results": true,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04019444"
    },
    {
      "nct_id": "NCT05289037",
      "title": "COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (B.1.1.529)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (B.1.351)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 bivalent (wildtype and Omicron BA.1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM [B.1.351]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM/D614",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM/D614+B.1.351",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.351",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.529",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.617.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride, 0.9%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1270,
      "start_date": "2022-03-30",
      "completion_date": "2023-11-27",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05289037"
    },
    {
      "nct_id": "NCT07703475",
      "title": "A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID -19"
      ],
      "interventions": [
        {
          "name": "RVX-sCPD9",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-09-05",
      "completion_date": "2027-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-09-24T02:52:32.992Z",
      "location_count": 4,
      "location_summary": "New York, New York • Durham, North Carolina • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07703475"
    }
  ]
}